Physician profile
Alan S Hoffman
NPI 1447351853
$12,429.08
in general payments reported to CMS, 2019-2025
51 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $2,458 · 2021: $2,448 · 2022: $1,537 · 2023: $1,694 · 2024: $1,166 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,107.55 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,652.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,314.05 | 2019-2024 | Farxiga |
| Pfizer INC. | $752.01 | 2019-2025 | |
| Lilly USA, LLC | $668.08 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.77 | 2019-2025 | Jardiance |
| Radius Health, INC. | $393.98 | 2019-2025 | Tymlos |
| Abbvie INC. | $374.80 | 2019-2025 | |
| Amarin Pharma, INC. | $361.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $336.65 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $327.06 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Otsuka America Pharmaceutical, INC. | $302.78 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $253.43 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $252.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $242.72 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.